These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11419433)

  • 1. Optimal treatment of acute coronary syndromes--an evolving strategy.
    Boden WE; McKay RG
    N Engl J Med; 2001 Jun; 344(25):1939-42. PubMed ID: 11419433
    [No Abstract]   [Full Text] [Related]  

  • 2. Future trials of antiplatelet agents in cardiac ischemia.
    Throckmorton DC
    N Engl J Med; 2001 Jun; 344(25):1937-9. PubMed ID: 11419432
    [No Abstract]   [Full Text] [Related]  

  • 3. Ischemic coronary syndromes and SVG Interventions--do 2b/3a inhibitors miss the target?
    Topaz O
    Catheter Cardiovasc Interv; 2007 Apr; 69(5):630-1. PubMed ID: 17377986
    [No Abstract]   [Full Text] [Related]  

  • 4. Beyond aspirin: how glycoprotein inhibitors ease acute coronary syndromes.
    MacCallum EM; Hanlon SJ; Byrne KH
    Nursing; 1999 Dec; 29(12):34-9; quiz 40. PubMed ID: 10797693
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
    Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953
    [No Abstract]   [Full Text] [Related]  

  • 6. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
    Gambhir DS; Mukhopadhyay S
    Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774
    [No Abstract]   [Full Text] [Related]  

  • 7. Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
    Ramanathan A; Kleiman NS
    Indian Heart J; 1998 Oct; 50 Suppl 1():45-56. PubMed ID: 9824907
    [No Abstract]   [Full Text] [Related]  

  • 8. Advances in antiplatelet therapy for acute coronary syndromes.
    Clem JR; Falls S
    S D J Med; 1998 Jul; 51(7):233-4. PubMed ID: 9676157
    [No Abstract]   [Full Text] [Related]  

  • 9. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
    Young JJ
    J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract]   [Full Text] [Related]  

  • 11. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM; Topol EJ
    Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
    [No Abstract]   [Full Text] [Related]  

  • 12. The TARGET trial: hit or miss?
    Moliterno DJ; Topol EJ
    Eur Heart J; 2002 Jun; 23(11):835-7. PubMed ID: 12042001
    [No Abstract]   [Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa inhibitors: current indications and future prospects.
    Reginelli JP; Topol EJ
    Am J Med; 2000 Aug; 109(3):252-4. PubMed ID: 10974193
    [No Abstract]   [Full Text] [Related]  

  • 14. Minimally invasive bypass surgery.
    Dragu RE
    N Engl J Med; 2002 Dec; 347(26):2165-8; author reply 2165-8. PubMed ID: 12501850
    [No Abstract]   [Full Text] [Related]  

  • 15. Will blocking the platelet save the diabetic?
    King SB; Mahmud E
    Circulation; 1999 Dec 21-28; 100(25):2466-8. PubMed ID: 10604881
    [No Abstract]   [Full Text] [Related]  

  • 16. Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors.
    Roe MT; Moliterno DJ
    J Thromb Thrombolysis; 1999 Jun; 7(3):247-57. PubMed ID: 10373718
    [No Abstract]   [Full Text] [Related]  

  • 17. The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty.
    Fischman DL; Savage MP
    JAMA; 1997 Aug; 278(6):518-9. PubMed ID: 9256229
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiographic predictors of adverse outcomes in the modern interventional era.
    White CJ
    J Am Coll Cardiol; 2003 Sep; 42(6):989-90. PubMed ID: 13678917
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes.
    Kereiakes DJ; McDonald M; Broderick T; Roth EM; Whang DD; Martin LH; Howard WL; Schneider J; Shimshak T; Abbottsmith CW
    Am Heart J; 2000 Feb; 139(2 Pt 2):S53-60. PubMed ID: 10650317
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.